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Abstract
Background: The blood pressure rapid intensive lowering and normal treatment for mood and cognition in
persistent depression (BRILiANT mood study) was devised as a pilot study to investigate the feasibility and
safety of intensive blood pressure lowering as treatment for persistent mood and cognitive symptoms in older
adults with major depressive disorder and to assess the availability of this population for recruitment. In
addition, the relationship between reduced blood pressure and the change in cerebral blood flow and mood
was to be investigated.
Methods: A single centre pilot randomised controlled trial (RCT), with two parallel groups of intensive or
normal treatment for hypertension, recruiting from primary and secondary care and newspaper advert, with an
aim of recruiting 66 participants, was observed in this study. At the end of the recruitment period, in order to
explore the reasons for failure to recruit to target, surveys were developed and issued to those involved in
recruitment.
Results: Recruitment rates were lower than expected which led to the study being expanded to further areas
and opened to self-referral via advertisement. However, because of better management of hypertension due
to changes in the UK Quality and Outcomes Framework guidelines for blood pressure treatment, few eligible
patients were identified and the study closed at the end of the recruitment period, with 13 participants
consenting, but 12 failing screening resulting in one recruited participant.
(Continued on next page)
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Conclusions: Overall, the BRILiANT mood study was found not to be feasible, and results suggest that the
expected patient population no longer exists. To overcome such recruitment difficulties, a prompt
commencement of a study after funding so no relevant care changes occur might help prevent similar
problems in future studies. In addition, self-referral, in this case via advertisement in papers, may be a useful
tool to increase response rate. When recruiting in primary care, direct access to primary care databases, in a
secure and anonymised way, may enable more effective screening. Ultimately, the BRILiANT mood study was
shown not to be feasible; this was a useful conclusion from this pilot study.
Trial Registration: ISRCTN 64524251; UKCRN Portfolio No: 13284
Keywords: Depression, Hypertension, Cognitive, Mood, Recruitment, Randomised controlled trials, Pilot
Background
Residual mood and cognitive symptoms commonly per-
sist after acute treatment of major depression [1], and
such persistence is clinically important, being linked
with higher rates of relapse [2, 3], worse psychological
functioning [4] and overall poorer longer term outcomes
[5–8]. Whilst factors causing symptom persistence in
middle-aged and older adults is not fully understood,
there is robust evidence that it is strongly related to
cerebrovascular disease [9] and prospective studies of
vascular diseases have reported that previous major
depression or depressive symptoms predicts a two- to
threefold increase in coronary heart disease and stroke
disease [9]. White matter hyperintensities (WMH),
which are regions of high intensity (lesions) seen in the
white matter of the brain in magnetic resonance imaging
(MRI) scans, are increased in depression [10]. The bur-
den of WMH predicts persistence [11] and worsening of
depressive symptoms [12], as well as incident depressive
episodes [12, 13]. The neurocognitive deficits in depres-
sion have also been associated with WMH [14–19]. In
addition, cognitive impairment in general has been re-
lated to vascular risk factors [20], and especially to
hypertension, WMH are also strongly related to hyper-
tension [21]. MRI studies have reported reduced cerebral
blood flow in older adults [22] with evidence that treat-
ment can increase the blood flow suggesting that the
adverse effects may be reversible [22]. Although other
biological and psychological factors may be important in
major depression, cerebrovascular disease evidenced by
the presence of WMH appears to be an important and
potentially treatable cause of persistent mood and cogni-
tive symptoms. Hypertension is a well-established risk
factor for cognitive decline in older adults [23], and
deficits in executive function are those most frequently
related to this [20]; it occurs in about 50 % of adults over
50 [24] and of these about half are inadequately treated
and so have persistent high blood pressure (BP) [24].
Hypertension causes structural vascular adaptation with
remodelling and hypertrophy leading to arteriolar
luminal narrowing and wall thickening. This leads to
compromised cerebral blood flow (CBF). Evidence
suggests that BP lowering to the normal range may
reverse these changes, with two studies in hypertension
reporting improved CBF at 6 months of BP lowering
[25,26] and one found improved cognition as well [25].
Evidence suggests that the use of antihypertensive
medication can improve mood, cognition and WMH by
lowering blood pressure, perhaps via improved cerebral
perfusion [25] and this can be measured in the brain
using arterial spin labelling (ASL) [27]. No previous
studies have examined BP lowering as a treatment
strategy in depression.
Therefore, we planned a pilot and feasibility study (the
BRILiANT mood study) as a randomised trial investigat-
ing intensive BP lowering as an augmentation strategy in
older people with hypertension and major depression
with persistent symptoms. The objectives were to assess
the feasibility and safety of a treatment intervention,
intensive blood pressure lowering as a treatment for
persistent mood and cognitive symptoms in older people
with major depressive disorder (MDD) and assess the
availability of the population for recruitment. Secondary
objectives were to investigate the relationship between
reduction in BP and change in cerebral blood flow and
correlations between cerebral blood flow and mood.
Despite running for its full-intended duration, and
concerted efforts made by the study team to improve
recruitment, the trial failed to recruit adequate partici-
pants, with only one participant enrolled and completing
the trial. Reported here is an overview of the study
design and recruitment strategy, along with the outcome
of surveys conducted to investigate the failure to recruit.
The ‘lessons learned’ from this will be discussed, in order
to inform recruitment protocols and strategies for
similar future trials.
Methods
Protocol design
The BRILiANT mood study was designed as a single
centre pilot randomised controlled trial with parallel
groups of two different antihypertensive treatments in
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older depressed patients with hypertension. A PROBE
(prospective randomised open blinded end-point) design
was used. Participants for the study were to be recruited
from both primary and secondary care. It was approved
by the National Research Ethics Service Committee
North East—Newcastle & North Tyneside 2 (REC
reference 12/NE/0292) and screening begun in May
2013 for a duration of 16 months.
Objectives
Primary objectives
This study was designed as a pilot trial to assess the
feasibility and safety of a treatment intervention, inten-
sive blood pressure lowering as a treatment for persist-
ent mood and cognitive symptoms in older people with
major depressive disorder (MDD), and assess the
availability of the population for recruitment, in accord-
ance with the documented purpose of a pilot study [28].
Feasibility was to be measured by overall recruitment to
the trial and recruitment rate; safety was to be measured
by recording of all adverse events in participants and
carefully determining their relationship to the interven-
tion to determine if they were suspected adverse reac-
tions and by recording dropout rates during the trial.
Secondary objectives
Secondary objectives included investigating the relation-
ship between reduction in BP and change in cerebral
blood flow and correlations between cerebral blood flow
and mood.
Treatment interventions
Participants, who were older people (aged 50–80) with
major depressive disorder and persistent mood symp-
toms, continued with their current antidepressant treat-
ment and were randomised into the intensive or
standard blood pressure (BP) lowering groups. Random-
isation was conducted by the Newcastle Clinical Trials
Unit web-based system in a 1:1 ratio stratified by
severity (defined by a dichotomous variable indicating
whether the HAM-D score at screening was less than or
equal to 20). The use of computer-based blocked
randomisation generated a unique treatment number for
each participant, with four treatment groups for
randomisation. They were treated for 12 weeks with
study assessments blind to their treatment allocation.
Treatment for the standard group followed current
National Institute for Health and Care Excellence
(NICE) guidelines: for participants aged <55, an angio-
tension converting enzyme (ACE) inhibitor, e.g. lisinopril
or angiotension II receptor blocker (ARB), e.g. losartan,
was initiated and for those aged >55, a calcium channel
blocker (CCB) was initiated; the intensive group received
initial doses of amlodipine (5 mg) and lisinopril (5 mg)
daily, with BP monitored on a fortnightly basis and the
doses increased if the BP reading was >130/80 mmHg;
bendroflumethazide (2.5 mg) was then added daily, with
doxazosin/atenolol/spironolactone added to the treat-
ment regime as needed to lower blood pressure to <130/
80 mmHg. All study visits (eight for the intensive group
and four for the standard group) took place at the
Clinical Ageing Research Unit at the Campus for Ageing
and Vitality at Newcastle University. The intensive group
had extra visits to increase the BP medication more
quickly if the BP target had not been achieved. In
addition, an MRI scan and a neuropsychological battery
comprising 12 scales were undertaken at baseline and
12 weeks to assess the relationship of cerebral blood
flow changes to clinical measures. These two visits
lasted for 3 h, with the shorter review visits lasting
30 min each.
Outcome measures
The primary outcome measure was the score on the
Montgomery-Asbery Depression Rating Scale (MDRS)
[29] (completed at baseline, 6 and 12 weeks) at 12 weeks,
with secondary outcome measures of change in execu-
tive and memory function from baseline to 12 weeks,
cerebral blood flow, change in mood, change in 24-h
ambulatory blood pressure monitoring from baseline to
end of study, remission of depressed mood (defined as
MADRS <8) and Clinical Global Impression (CGI) [30]
severity and improvement. In addition, subjects com-
pleted the Beck Depression Inventory (BDI) [31] every
2 weeks.
Statistical issues
The planned sample size was 66 participants, with 33 to
be allocated to each group; a 10 % attrition rate was
factored into this calculation. This number was based on
recommendations for minimum numbers needed for
pilot clinical trials with continuous outcomes [32].
As this was a pilot study, the statistical analysis was
descriptive in nature, providing estimates of key trial
parameters to inform power calculations for a future
definitive trial [28]. In addition, correlation coefficients
were also to be calculated between blood flow measures
and measures of depression, executive function and
memory, and multivariate statistical techniques were
to be used to explore the possibility of producing a
smaller number of composite variables describing
neurocognitive function.
Inclusion and exclusion criteria
Individuals aged 50–80 were sought for this study, with
a history of MDD and defined as currently depressed.
All participants were to be on a stable single antidepres-
sant therapy and have hypertension (BP >140/90 mmHg)
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with no changes to any medication within the preceding
month and a Mini Mental State Exam (MMSE) [33]
score of >23. Potential participants identified with
another Axis I DSM-IV disorder (other than an anxiety
disorder), harmful use of drugs and/or alcohol in the
preceding 12 months, on two or more antihyperten-
sive drugs, dementia, stroke, bipolar or psychotic
disorder, renal or hepatic impairment, pregnancy, use
of other investigational study drugs, MRI contraindi-
cations or previous participation in this study were
excluded.
Recruitment and screening
In all, 20 primary care practices (Table 1) carried out
screening for this study, with additional screening
undertaken in secondary care psychiatry services within
NHS trusts and in six secondary care medical clinics in
Newcastle and Gateshead. In addition, local newspaper
advertisements were also used to identify potential
patients. Screening was a three-step process: the initial
screening (taking place in primary and secondary care)
consisted of a basic screen using the inclusion/exclusion
criteria; the second stage was a more detailed telephone
screening to check eligibility; and the final, more detailed
screening stage took place at the initial study visit.
Primary care
Research active practices were identified through the UK
Primary Care Research Network (PCRN) and sent infor-
mation about the study. Those practices interested
carried out a computer screen of patient lists using all
key study entry criteria. Antidepressant therapy was used
as a proxy for depression coding, as searches using
coding proved problematic. Potential participants identi-
fied as meeting the criteria and deemed suitable by their
primary care team were then sent an invitation letter
from their GP inviting them to contact the study team if
they wished to participate. A further telephone screening
was then conducted on all respondents to check eligibil-
ity (confirmation of age, current medication and mood),
and if applicable, a participant information sheet sent to
the individual and an appointment made for baseline as-
sessment. If eligible to enter the study, informed written
consent was obtained by a member of the study team.
It should be noted that during the course of the study,
changes to the structure of the UK National Health
Service included the abolition of Primary Care Trusts
and the introduction of Clinical Commissioning Groups
(CCG), who are clinically led statutory groups respon-
sible for the planning and commissioning of healthcare
services for their local area. Although the geographical
areas remained virtually unchanged, it did mean a
reorganisation of the management systems in place.
Some services of CCGs were taken over by the North
East Commissioning Support Unit (NECS), who provide
support to CCG’s in order to improve patient and
healthcare outcomes. In addition to this, changes were
introduced to the Quality outcomes Framework (QoF)
for the treatment of hypertension in primary care.
As all study visits were being carried out at the Campus
for Ageing and Vitality in Newcastle upon Tyne, re-
cruitment was confined to Newcastle, Northumberland,
Sunderland and northern areas of the Tees, Esk and Wear
Valley Trust. We also added further CCGs: North Durham,
Durham Dales, Easington and Sedgefield, during the study,
in an attempt to widen the net for recruitment (Table 1).
Table 1 Population distribution across total CCG population and participating GP practices
CCG area Total population
in CCGs
Estimated population
% of 50–80-year-olds
from total CCG
population
Total GP
practices
in CCGs
No. of
participating
GP practices
Total practice
population from
participating
GP practices
Estimated population
% of 50–80-year-olds
from participating
GP practices
NHS Durham Dales, Easington
and Sedgefield CCG
287,365 51726 42 0 0 0
NHS Gateshead CCG 234,131 35120 35 3 20,711 3107
NHS Hartlepool and
Stockton-On-Tees CCG
286,993 45919 42 0 0 0
NHS Newcastle North and East CCG 152,211 18265 18 0 0 0
NHS Newcastle West CCG 130,933 18331 18 1 10,239 1433
NHS North Durham CCG 246,262 41865 32 1 1,663 283
NHS North Tyneside CCG 215,349 34456 29 2 21,058 3369
NHS Northumberland CCG 321,824 61147 46 6 30,967 5884
NHS South Tees CCG 288,784 46205 50 0 0 0
NHS South Tyneside CCG 154,881 26330 30 3 20,209 3840
NHS Sunderland CCG 284,682 45549 55 4 26,389 4222
Total population 2,603,415 424,913 397 20 131,236 22,138
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Secondary care
Those in secondary care were screened for potential
eligibility using all key study entry criteria by the North
East of England Mental Health Research Network
(MHRN) and Dementias and neurodegenerative Dis-
eases Research Network (DenDRoN) by examining both
paper and computerised clinical notes.
An invitation letter was then sent to the individual by
their treating consultant if he/she deemed such an
approach appropriate. The same procedure as for pri-
mary care was then implemented.
Enhancing recruitment
During the course of the study, in order to address diffi-
culties experienced in recruiting participants, additional
strategies were implemented. In March 2014, recruit-
ment was broadened to three further CCG areas, so that
in total, we had approval to recruit from seven CCGs in
the North East England area. In order to approach GPs
directly about the study, the chief investigator presented
at one GP forum, and the trial manager and clinical
support officer from DenDRoN gave short presentations
to all GPs separately at another GP forum, which were
both held locally. Meetings were also held by the CI and
study team with consultant psychiatrists, MHRN and
DeNDRoN staff and PCRN/NECS staff. In addition to
recruitment from primary care and psychiatry services,
attempts were made to identify patients with hyper-
tension through acute hospital clinics (e.g. diabetes,
cardiovascular) in Newcastle and Gateshead from
December 2013. Finally, direct recruitment from the
public via advertisements in regional newspapers was
also tried.
Advert
Advertisements were placed in three local newspapers:
the Chronicle, Journal and Metro, during December
2013, January and March 2014, for a total of 4 weeks.
The Evening Chronicle is read by more than 170,000
readers daily, the Metro which is a free paper has a daily
circulation of nearly 58,000 and 23,000 copies of the
Journal are sold every day. We also took advantage of
the Journal Live page, which included a landing page
directly to the BRILiANT mood study on the Newcastle
Biomedicine webpage; a total of 41 ‘hits’ were recorded.
We also used a pilot scheme offered to us without
charge by NIHR CRN, using a text-back service. Poten-
tial participants were asked to text ‘BPMood’ to a
dedicated text number, through which the research team
then contacted them.
Surveys
Following the end of the study recruitment period, the
Trial Steering Committee (TSC), which had suggested
and supported the above changes in recruitment strategy,
requested that the research team sought to explore the
reasons for the trial’s failure to recruit enough eligible
participants. Questions were developed by the study team,
based upon areas of concern that had emerged during the
recruitment phase of the study (such as search criteria
used, changes to QoF BP guidelines, visibility of the study,
participant contact method and engagement of GP
practices), using successive iteration which was approved
and finalised by the TSC. Different surveys were
constructed, in order to investigate the experiences of
those services involved (and representative services not
involved) in recruitment to this trial. These surveys were
sent electronically via SurveyMonkey, along with a study
information sheet, to GP practices that screened for the
study (19), GP practices who did not (40, matched to
the same geographic healthcare (CCG) areas), consul-
tants (17) and MHRN staff who screened for the study
(11). All surveys were anonymous and open for
responses for 3 weeks.
Results
Primary objectives
The trial was found not to be feasible, with only one
participant recruited. This participant completed all
assessments with no adverse events.
Secondary objectives
All clinical and imaging data were collected but with
only one participant; no analysis was attempted.
Recruitment
The study recruitment ran from May 2013 to August 2014.
Recruitment from primary care
In the CCG areas approved for the study, the total
number of potentially available GP practices is 397 with
a population of approximately 425,000 of 50–80-year-
olds. From this, 20 practices participated with a popula-
tion of 22,000 (Table 1).
Screening carried out in primary care (Fig. 1) yielded
1053 potentially eligible participants, of which some
were ruled out by the GP: 448 of these were sent an
invitation letter from the GP practice. From this, 56 (5 %
of those identified) contacted the study team to express
interest, and telephone screening was carried out on 51.
As a result of the screening, 7 declared no interest in
participating and 33 were ineligible. In total, 11 (1 % of
those initially identified) were found to fit the eligibility
criteria, and from this, 6 were consented into the trial.
Following more detailed screening at the initial study
visit at the Clinical Ageing Research Unit, further
exclusions were made due to either controlled blood
pressure, or no current depressed mood; only 1 (about
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0.1 % of those identified) was found to be suitable and
randomised into the study.
Recruitment from secondary care
In areas approved for the study, 26 mental health
consultants, from four NHS Trusts, for younger and
older adult patients were approached, of whom 19
agreed to participate.
In secondary care (Fig. 2), a total of 180 potential
participants, of which 123 were identified by DeN-
DRoN and 57 by the MHRN, were screened, and 70
were contacted. From these, 49 (27 % of those iden-
tified) contacted the study team to express interest,
with 45 screened via telephone. This resulted in 18
being found to be not eligible and 21 declaring the
wish not to proceed further. In total, 6 (3 % of those
identified) were found to be eligible, and 5 were
consented into the study. As a result of the more
detailed screening at study visit 1, none were found
to be suitable, and none were randomised into the
study.
Advert
As a result of advertising (Fig. 3), 40 people contacted
the study team to express interest. From these, 37 were
telephone screened, with 31 found not to be eligible and
2 people declaring no further interest. From this recruit-
ment stream, 4 (10 % of those identifying themselves to
the team) were found to be eligible, and 2 were con-
sented into the study. As a result of more detailed clin-
ical screening at study visit 1, neither was found to be
suitable, and none were randomised into the study.
Overall, from all recruitment streams, 1233 poten-
tially eligible participants were identified from GPs,
consultants and self-referrals from the general pub-
lic, with 151 of these telephone screened. From this,
a total of 21 eligible participants were identified; of
these, 13 were consented into the study. Ten failed
further screening as blood pressure was controlled,
two participants failed screening for depression cri-
teria. The study closed at the end of the planned re-
cruitment phase having enrolled one participant
(Figs. 1, 2 and 3).
Fig. 1 Consort diagram showing screening and recruitment figures from primary care
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Surveys to explore reasons for recruitment difficulties
GP practices that screened for eligible participants
In all, 10 responses were received from the 19 surger-
ies contacted (53 % response rate), with one respond-
ent not completing the survey. The responses were
received from practice managers and not from GPs
themselves. They indicated that the majority (8/9,
89 %) felt the participant search criteria was clear and
easy to follow although a small number noted their
computer systems caused difficulties, but nothing
could have been done differently by the study team
to help with identifying patients (100 % of respon-
dents who answered). Most of those who responded
stated that they contacted all eligible participants (6/
9, 67 %), and the managers felt the changes to the
QoF BP guidelines had not made a difference to how
patients were treated (7/8, 87.5 %). A wide range of
reasons were given for why potentially eligible partici-
pants were not contacted, with the patient having
another significant illness also present being cited
most. The number of visits involved for the partici-
pants, and the differing ways a diagnosis of depres-
sion is recorded in clinical notes emerged as barriers
to screening for this study.
GP practices who did not screen for eligible participants
In all, 12 responses were received (30 % response rate).
Most of the respondents (67 %) had heard of the study,
and of those that had not 3/4 (75 %) indicated that they
would have been interested in taking part. Most respon-
dents did not give a reason for why they felt unable to
participate, but for those that did, the main reasons cited
were there was no time to do research and concern
about the burden on the study subjects.
MHRN staff who screened for the study
In all, 6 responses were received (55 % response rate).
All respondents felt that the search criteria were clear
and easy to follow. However, over half (67 %) reported
that they had encountered problems when screening,
with BP not being recorded (3/5, 60 %) and a small
number of people found to be eligible (2/5, 40 %) cited
as the main reasons for difficulty identifying study sub-
jects. It was also noted that the number of study visits
might have been too onerous.
Consultants
In all, 4 responses were received (24 % response rate). All
were interested in recommending suitable participants for
Fig. 2 Consort diagram showing screening and recruitment figures from secondary care
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this study. Two respondents specified why they felt most
patients would be excluded from this study, with one
citing normal BP and one the restrictive criteria for all
intervention studies.
Discussion
The BRILiANT mood study was developed as a pilot
and feasibility randomised controlled trial (RCT) to
investigate using rapid blood pressure lowering to allevi-
ate persistent mood and cognitive symptoms in major
depressive disorder in older adults. Despite the expecta-
tions of an available population (Table 1) based on the
then current NICE Clinical Guideline [24], difficulties
were experienced in the process of recruitment at
several stages. The study team and TSC identified
recruitment difficulties and throughout the recruitment
period implemented several new strategies to try and
improve recruitment. Attempts by the study team to
improve recruitment had mixed results. Expanding
recruitment areas geographically had little impact on the
numbers of eligible participants identified, but the use of
direct recruitment via the advert yielded a good response
rate. The responses from the surveys suggested that
most clinicians were satisfied with the study design,
though some felt any clinical trial is too much of a
burden e.g. ‘patients do not like to travel and would be
put off by the number of visits’. Positively then, the study
design itself did not cause significant problems with re-
cruitment; the one eligible subject completed all study as-
sessments without any problems or adverse events, and
the search criteria were appropriate. Nevertheless, the fact
that several participants identified did not meet the
screening criteria, e.g. wrong age and presence of demen-
tia, suggests that the criteria were not applied consistently.
In spite of these efforts, the study closed, having recruited
only one participant in the planned time period.
Twenty GP practices (about 5 % of available GP
practices) agreed to participate in the study (NECS
informed the study team that all research active prac-
tices were given information about the study; however,
they do not maintain records of who declined, or
reasons why). This limited support was felt to be a limit-
ing factor in this study. Using ONS and CCG population
data, Table 1 shows the population distribution across
the CCG areas approved for this study. Based on the of-
fice for National Statistics data [34], the total population
Fig. 3 Consort diagram showing screening and recruitment figures from advertisements in local newspapers
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for the 20 GP practices is approximately 1.5 million, of
whom approximately 15 % are aged between 50 and
80 years old (based on the data obtained from Public
Health England [35], with the CCG data provided by
NECS [36]). This provided us with a potential target
population of about 22,000 who were potentially
screened by primary care, and of these, 1053 (about 5 %)
were identified as potentially eligible by screening (see
Fig. 1). These data suggest that at the recruitment rate
we achieved (one randomised subject from 5 % of prac-
tices), we would only have 20 randomised subjects if we
had engaged all GP practices in the North East of
England. This suggests that we would have needed to
screen from over three times the actual number of
patients existing in our target age group in the North
East to obtain our 66 subjects, leading to the conclusion
that currently such a study is not feasible.
A key question then is whether the target population
(50–80-year-olds with inadequately treated hypertension
and major depression with residual depressive symp-
toms) exists and was not identified (a problem with the
recruitment process) or does not actually exist. When
the study team set out to investigate reasons behind the
poor recruitment, it was discovered that there had been
important recent changes in the management of blood
pressure in primary care at the instigation of the UK
Department of Health, which had changed the Quality
and Outcomes Framework (QoF) for treatment of hyper-
tension. The QoF is the annual reward and incentive
programme in the UK in primary care, linking measures
of performance to funding. QoF awards surgeries achieve-
ment points for various health outcomes including
 Managing some of the most common chronic
diseases, e.g. asthma, diabetes
 Implementing preventative measures, e.g. regular
blood pressure checks
As part of the 2013/14 contract changes, the Depart-
ment of Health (DH) implemented changes to the QOF
effective from 1 April 2013 [37]; one of which was the
BP threshold was lowered from 150/90 to 140/90 mmHg
for patients aged 79 or under, directly affecting the study
target population. This was implemented just as the
study was about to start. Effectively, primary care was
incentivised to identify and treat people with hyperten-
sion in the age group the study was trying to recruit
from. Although practice managers responding to the
survey did not think this as a factor, the fact that five
out of six subjects consented from primary care and five
out of five from secondary care failed eligibility because
of normal blood pressure suggests that better BP
management was a significant factor. Although numbers
are small, it indicates that most people recorded as
hypertensive in NHS records may now have normal
blood pressure. The QOF change is likely to have been
an important factor in causing recruitment difficulty and
suggests that currently in the UK, the target population
for this study may not exist in sufficient numbers to
make such a study feasible.
A further problem that emerged from the survey
responses was the variation in the diagnosis recording.
In particular, it was difficult to identify patients with
major depressive disorder due to the differing ways it is
recorded in clinical notes. In theory searching, using
coding as a search parameter could alleviate this;
however, with over 400 different relevant codes in use,
this is not an easy option to apply. Furthermore, GPs
may be reluctant to use coding systems to classify
psychological diagnoses [38]. In this study, medication
(use of antidepressants) was used as a proxy to try to
overcome this barrier and allowed identification of
people who were potentially being treated for depres-
sion, although many were not depressed when screened,
suggesting that as with hypertension, many who were
recorded as depressed did not currently have low mood
and so searching on the basis of antidepressant medica-
tion may not have been an effective enough method to
detect those who were symptomatic.
However, there were also process problems in trying to
identify potential participants. Recruitment into clinical
trials can be problematic [39], particularly for participants
with severe mental illness [40], with many factors influen-
cing the decision to participate [41]. A study in the same
area at the same time as this one found that it was much
more difficult to recruit people from primary care with
depression [42] than with a diagnosis of hypertension
(although as seen, most would now be treated and not
hypertensive). Given the nature of depression, with symp-
toms such as amotivation and anergia, such problems are
not surprising, and we found that less than 10 % of those
whom consultants thought were eligible were actually
willing to participate. In addition to this, further problems
can arise when recruiting participants from primary care,
with difficulties with the quality of databases and com-
puter searches and researchers often overestimating the
population of patients available for a particular study [43],
and GPs excluding potentially eligible participants from
trials [44]. In our study, although the study managers
stated they thought the search criteria were clear and easy
to follow, over 10 % of identified subjects failed telephone
screening for reasons which should have been identified
by the computerised screening, e.g. wrong age or on two
or more antihypertensives (see Fig. 1). This indicates that
the criteria were not accurately applied in practice and
raises the possibility that potential subjects were also
missed. Finally, recruitment using advertising did not yield
a significant number of suitable participants [45].
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The final notable barrier, which was felt to have
contributed to recruitment problems, is that of the time
delay experienced between the writing of the grant
proposal and the start of the study. This study experienced
a delay of 2 years which it took to finalise contracts and
obtain relevant statutory approvals, which allowed
changes to take place (notably in the QoF guidelines)
which affected recruitment. Having identified an expected
available population, it seems to have disappeared by the
time the study started. When identified potentially eligible
participants contacted the study team, then the symptoms
were no longer present, resulting in many participants
being screened out at various stages (e.g. telephone
screening, baseline screening) who had been identified as
eligible. Despite concerns that the number of study visits
may have been too onerous, this did not deter partici-
pants, as most were willing to attend, but failed at screen-
ing, with the one recruited participant completing the
study suggesting that this might not be the case.
Conclusions
It appears the patient population required for this study
may no longer exist in sufficient numbers. The length of
time taken to start this study following funding allowed
the QoF changes to take place was likely a contributing
factor. In addition, the process of patient identification is
cumbersome and inaccurate. Future studies recruiting in
primary care would benefit from direct access to primary
care databases, in a secure and anonymised way, and
could allow for a pre-screening of records to determine
the number of potentially eligible participants prior to the
start of the study. Direct recruitment via advertisement
may be a useful tool to increase response rate; although in
this study, large numbers were identified but no one was
finally eligible. Overall, although ultimately the BRILiANT
mood study was shown not to be feasible, this was a useful
conclusion from this pilot study [28].
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